Method To Detect Malignant Tumors Earlier May Help Breast- And Prostate-Cancer Patients

April 14, 1998

DALLAS * April 14, 1998 ** Earlier detection of malignant tumors may be possible with a new method developed by UT Southwestern Medical Center at Dallas researchers that identifies cancer cells in blood.

Using a laser to identify cancerous cells, the scientists found that patients with breast and prostate cancer had significantly more epithelial cancer cells in their blood than people who are disease free, said Dr. Jonathan Uhr, professor of microbiology and internal medicine and lead author of the study in today's issue of Proceedings of the National Academy of Sciences. The investigators reported the test is more sensitive than currently available screening tests.

"The major potential use of this test would be to detect early tumors," said Uhr, holder of the Raymond Willie and Ellen Willie Distinguished Chair in Cancer Research, in Honor of Laverne and Raymond Willie Sr. "It's an extremely sensitive test. It can detect one cancerous epithelial cell in a milliliter of blood."

To identify the cells in the blood of cancer patients, the investigators treated blood samples with an antibody-coated iron particle to search for the cancer cells and then used a laser to turn malignant cells a different color than the rest of the sample. This allowed researchers to pick out cells with tumor characteristics. They confirmed findings by microscopic examination.

"Our major goal now is to fine-tune and automate the test before using it in high-risk patient groups to determine if we can pick up shedding of malignant cells from the primary tumor at a very early stage?possibly before detection of the primary tumor in some patients," Uhr said.

The scientists also showed that in all 12 breast-cancer patients in the study there was a positive correlation between the number of tumor cells in the blood and the clinical status: When the tumor was growing, the level of cancer cells in the blood was high. When they were effectively treated with chemotherapy, the cells disappeared. When relapse occurred, the count escalated again.

Comparing patients with malignancies found only in one organ with those whose lymph nodes were invaded by the disease and with patients whose cancer had spread to distant parts of the body, the researchers found a significant difference in the number of cancerous epithelial cells. The more advanced and invasive the disease, the greater the number of cancerous cells in the blood.

"One advantage of this method is that we can count the number of tumor cells in the blood, and it appears to be correlated in general with the extent of the tumor clinically," Uhr said. "Therefore, this test might also be useful to clinicians to monitor treatment.

"The prognostic significance of this test is that by counting the cells and characterizing them, it may be possible to predict the progressive states of the disease," he said. "But it will take many more patients and many years of research to find out if this method will work in that way and if it will be true for cancers other than breast and prostate."

The other researchers involved in the study were: Dr. Emilian Racila, assistant instructor of microbiology at the Cancer Immunobiology Center; Dr. David Euhus, assistant professor of surgical oncology; Dr. John McConnell, chairman of urology, holder of the E.E. Fogelson and Greer Garson Fogelson Distinguished Chair in Urology and director of the Dr. Bob Smith Foundation Center for Prostate Research, the George M. O'Brien Urologic Research Center and the Prostate Disease Center; Dr. Arthur Weiss of Jefferson Medical College of Thomas Jefferson University, Philadelphia; Dr. Chandra Rao and Dr. Leon Terstappen of Immunicon Corp.
This news release is available on our World Wide Web home page at

To automatically receive news releases from UT Southwestern via e-mail, send a message to Leave the subject line blank and in the text box, type SUB UTSWNEWS

UT Southwestern Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to